Stem cell research is a rapidly growing field of study with huge potential for clinical solutions, taking advantage of the power and flexibility of pluripotency and self-renewal. Induced pluripotent ...

Induced pluripotent stem cells (iPSCs) are a “starting material grail” for advanced therapies. That’s according to Sven Kili, chief development officer at CCRM, the Canadian regenerative medicine ...

The growing burden of neurodegenerative diseases has intensified the need for translational models that replicate human biology more accurately. Traditional approaches often fail to predict clinical ...

Induced pluripotent stem cells (iPSCs) are young cells created by reprogramming old cells into a stem cell-like state via various transcription factor cocktails. And for many applications – certainly ...

Since their discovery in 2006 by Takahashi and Yamanaka, induced pluripotent stem cells (iPSCs) have seen a remarkable surge in their application within academic and industrial research. Generated by ...

Nicola Bevan is a manager in the BioAnalytics Applications Group (Royston, UK) of Sartorius (Göttingen, Germany). Her team is focused on the development of novel applications and delivering ...

Traditional growth factors and cytokines used in regenerative medicine and cell therapy manufacturing face several quality issues, including lot-to-lot variability, potential contamination with ...

According to the Alliance for Regenerative Medicine, more than 1300 clinical studies for regenerative medicine and advanced therapies, including autologous and allogeneic cell therapies, are ongoing ...